encorafenib + binimetinib + pembrolizumab

This is an investigational combination therapy composed of **encorafenib** (a small molecule BRAF inhibitor), **binimetinib** (a small molecule MEK inhibitor), and **pembrolizumab** (a monoclonal antibody checkpoint inhibitor targeting PD-1). The combination is being evaluated as a first-line treatment for unresectable locally advanced or metastatic melanoma with BRAF V600 mutation. Encorafenib inhibits the activity of BRAF V600-mutant kinase, blocking signalling that promotes cancer cell proliferation[2][3][5][7]. Binimetinib inhibits MEK1/2, further disrupting the RAS/RAF/MEK/ERK pathway[2][3][7]. Pembrolizumab binds to PD-1 on T cells, preventing its interaction with ligands and thus enhancing immune-mediated anti-tumor responses[2]. The triplet regimen is under phase 3 clinical evaluation in the STARBOARD trial, aiming to determine if combining targeted and immunotherapy improves outcomes over monotherapy in BRAF V600-mutant melanoma[2][5][7].